Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Marrow Derived AC 133+ and MNC Implantation in Acute Myocardial Infarction
NCT01187654Phase 3Completed
- Sponsor
- Royan Institute
- Start
- May 2009
- Primary completion
- Sep 2012
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous CD133+ bone marrow-derived stem cells in myocardial infarction (MI) (3 arms), sponsored by Royan Institute. Primary endpoint: Left Ventricular Ejection Fraction at 6 months. Started May 2009; status: completed.
02
Drugs
autologous CD133+ bone marrow-derived stem cells
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT01187654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01187654.